drugset / Trial / NCT05067257
Study to Assess Epidural Resiniferatoxin for the Treatment of Intractable Pain Associated With Advanced Cancer
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This Phase 2 study assesses the safety and efficacy of a single injection of Resiniferatoxin versus placebo for the treatment of intractable advanced cancer pain.
Timeline
- Start
- 2025-09
- Primary completion
- 2027-06
- Completion
- 2027-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Resiniferatoxin | Other / unclassified | 15 ug | Other |
| Subject | Resiniferatoxin | Other / unclassified | 20 ug | Other |
| Subject | Resiniferatoxin | Other / unclassified | 25 ug | Other |